Nanotechnological approaches against Chagas disease.
Over several thousand years, the flagellated Trypanosome cruzi-causative agent of Chagas disease-developed a complex life cycle between the reduviidae vectors and its human hosts. Due to their silent and hidden location, the intracellular amastigotes are mainly responsible for the nearly 50,000 annual deaths caused by the chronic chagasic cardiomyopathy. Chagas disease is the most important parasitic disease in the Americas, though treatments have not evolved towards a more efficient pharmacotherapy that (i) eradicates the scarce amastigotes present at the indeterminate/chronic form and (ii) employs less toxic drugs than benznidazole or nifurtimox. Nano-drug delivery systems (nanoDDS) represent useful means to selectively deliver the drug to intracellular targets. However, preclinical research in Chagas must be extended in order to improve the chances of a clinical implementation. The stages involved in this process are (i) selection of the appropriate drug for a specific parasite, (ii) development of a drug-loaded nanoDDS structure that displays the adequate pharmacokinetics, biodistribution and intracellular transit and (iii) selection of the right parasite form to target and the right stage of the disease for the treatment to be started. In this review we will critically overview the few research works published in the last 20years in the context of nanotechnology and Chagas diseases and highlight the gaps in knowledge towards the design of more efficient medicines to address this endemic.
Romero
Eder Lilia
EL
Programa de Nanomedicinas, Universidad Nacional de Quilmes, Bernal, Buenos Aires, Argentina. elromero@unq.edu.ar
Morilla
Maria Jose
MJ
D000666:Amphotericin B / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D014355:Chagas Disease / Q000188:drug therapy* / Q000469:parasitology; D002626:Chemistry, Pharmaceutical; D003906:Developing Countries; D016503:Drug Delivery Systems; D006321:Heart / Q000187:drug effects; D006801:Humans; D019344:Lactic Acid; D008081:Liposomes; D008863:Microspheres; D053758:Nanoparticles; D036103:Nanotechnology / Q000639:trends*; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D014344:Trypanocidal Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D014349:Trypanosoma cruzi
D008081:Liposomes; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D000666:Amphotericin B